Background: Amelanotic melanoma (AM) is a rare form of melanoma lacking pigment. Data on AM risk factors and factors predicting survival are limited.
Objectives: We sought to identify predictors of AM, survival differences in AM and melanotic melanoma, and AM-specific survival rates.
Importance: Insurance companies use prior authorizations (PAs) to address inappropriate prescribing or unnecessary variations in care, most often for expensive medications. Prior authorizations negatively affect patient care and add costs and administrative burden to dermatology offices.
Objective: To quantify the administrative burden and costs of dermatology PAs.